Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Akihiro Nishi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $134,811 — PROJECT SUMMARY (ABSTRACT) Contact network epidemiology is a compelling epidemiologic framework that aims to model dynamic interactions of people over their social networks in order to track infection cascades, especially for communicable diseases. Network-based simulations in contact network epidem…
Donna L. Farber · SCRIPPS RESEARCH INSTITUTE, THE · 2023 · $878,617 — Project Summary/Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), has exploded into a global pandemic causing significant loss of life, pronounced economic impact and significant long-term medical impacts which are still being char…
Zhi Q. Yao · JAMES H QUILLEN VA MEDICAL CENTER · 2023 — SUMMARY The overall goal of this proposal is to elucidate the mechanisms by which chronic HIV infection promotes telomere attrition and T cell aging, leading to hepatitis B virus (HBV) vaccine hypo-responsiveness. To this end, we will use a model that emulates HBV vaccine response in the setting of …
Siyuan Ding · WASHINGTON UNIVERSITY · 2023 · $393,750 — Project Summary Rotaviruses (RVs) are a medically important human pathogen and the predominant cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children worldwide. RVs are also a great model to interrogate the antiviral responses at the host mucosal surfaces. Our overall…
Craig A Elmets · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2023 · $185,625 — ABSTRACT Sunlight is the major environmental agent to which humans are exposed. Although it has beneficial effects (e.g. metabolism of vitamin D, energy necessary for life), chronic overexposure to the ultraviolet portion causes DNA damage, premature aging of the skin, immunosuppression and non-mela…
MYRON Scott COHEN · FAMILY HEALTH INTERNATIONAL · 2023 · $1,007,764 — This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) for implementation of the COVID-19 vaccine efficacy trial entitled “Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern.” With the global COVID-19 pan…
Stanley Xu · KAISER FOUNDATION RESEARCH INSTITUTE · 2023 · $664,451 — PROJECT SUMMARY/ABSTRACT Despite the success of the unprecedented COVID-19 vaccine rollout in the U.S., vaccine hesitancy is evident, partly due to safety concerns about severe adverse events (SAEs) surrounding the novel technology of mRNA COVID-19 vaccines and reports of blood clots following recei…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2023 · $708,799 — ABSTRACT Vaccines prevent hundreds of millions of illnesses and save millions of lives every year. Various types of licensed vaccines (live attenuated and inactivated pathogens, adjuvanted protein subunits) provide some level of protection against a variety of dangerous illnesses. However, there are…
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2023 · $731,376 — Abstract Influenza is responsible for significant morbidity and mortality worldwide every year and causes severe pandemics when new strains evolve that have not previously circulated in humans. The high viral mutation rate necessitates that new vaccines be generated based on the prevalence of circul…
Xiaojing J Gao · STANFORD UNIVERSITY · 2023 · $1,350,770 — Abstract The COVID vaccination campaigns have highlighted the promise of mRNA-mediated delivery as a novel therapeutic modality. One particular application is adoptive cell therapy, where immune cells are equipped with novel functions to treat diseases, e.g., expressing chimeric antigen receptors (…
Edward M. Schwarz · UNIVERSITY OF ROCHESTER · 2023 · $1,304,334 — Abstract Bone infection caused by Staphylococcus aureus remains the bane of orthopaedic surgery, as diagnostics, prophylactics and treatments have significant shortcomings that result in catastrophic outcomes for patients, and crippling healthcare costs. Although the incidence of infection following…
Charles M Rice · ROCKEFELLER UNIVERSITY · 2023 · $846,776 — Project Summary The yellow fever 17D live-attenuated vaccine has been administered to millions of people and is a highly successful and safe vaccine providing essentially life-long protection. However, the mechanisms of attenuation are poorly understood, and rare individuals suffer from sometimes f…
ROBERT J FONTANA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2023 · $377,396 — ABSTRACT Over the past 5 years, the DILIN Prospective and Retrospective studies have led to significant improvements in DILI causality assessment (e.g. RECAM, HCV/ HEV testing) and improved understanding of the risk factors and outcomes of DILI due to individual drugs and HDS products. Mechanistic i…
Ian J Mohr · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2023 · $436,140 — 7. PROJECT SUMMARY / ABSTRACT Regulation of gene expression at the level of translation allows cells and organisms to respond swiftly to physiological stress and changing environments. Indeed, differential translation of capped, polyadenylated mRNAs by eukaryotic ribosomes plays a critical role in b…
David K Gifford · THINK THERAPEUTICS, INC. · 2023 · $306,500 — Project Summary We propose to develop a new immunogenicity assay and machine learning based framework for creating tolerization vaccines for autoimmune diseases with improved population coverage. In collaboration with Harvard University and the University of Massachusetts Chan Medical School Diabete…
Rajesh Thippeshappa · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2023 · $99,000 — Abstract/Summary: Commonly used animal models of HIV-1 include infection of macaques with Simian Immunodeficiency Virus (SIV) or Simian-Human Immunodeficiency Virus (SHIV) containing HIV envelope (Env) or reverse transcriptase. These animal models have been extremely useful in understanding HIV path…
Charles Bix Shoemaker · TUFTS UNIVERSITY BOSTON · 2023 · $247,500 — Schistosomes are parasitic flatworms that cause a chronic, debilitating disease afflicting >200 million people in >70 countries. Since there are limited anti-schistosome drugs available and since these is no vaccine to prevent infection, we aim here to generate and test nanobody-based immunotherapeu…
ALAN THOMAS JOHNSON · HAWAII BIOTECH, INC. · 2023 · $203,485 — Abstract/Project Summary Along with the many benefits of a global economy hides the ever-present risk for the world wide spread of infectious disease. While significant outbreaks of the flu in the recent past involving millions of individuals could be contained, the emergence and rapid spread of th…
Michael R. Farzan · BOSTON CHILDREN'S HOSPITAL · 2023 · $221,250 — ABSTRACT Both private entities and academic groups are pioneering B cell editing for therapeutic purposes, either to express therapeutic antibodies from their native Ig loci, or other transgenes from an ectopic locus. BCR editing is currently performed with CRISPR/Cas system and a homology- directed…
Albert J. Auguste · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2023 · $262,294 — Abstract Orthobunyaviruses are an understudied genus in the order Bunyavirales that has no vaccines or therapies in clinical development. One of the prototype pathogens within this genus, as recently identified by NIAID, is Cache Valley virus (CVV). CVV is an emerging arthropod-borne virus that indu…